ALICIA (Acalabrutinib in CLL therapy)

Trial Identifier:	D8220R00021
Sponsor:	AstraZeneca
Start Date:	February 2021
Primary Completion Date:	December 2025
Study Completion Date:	December 2025
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia, Bashkortostan Republic	Ufa, Bashkortostan Republic, Russia, 450054
Russia, Kaliningrad region	Kaliningrad, Kaliningrad region, Russia
Russia, Khabarovsk region	Khabarovsk, Khabarovsk region, Russia, 680009
Russia, Komi Republic	Syktyvkar, Komi Republic, Russia
Russia, Krasnoyarsk region	Krasnoyarsk, Krasnoyarsk region, Russia, 660022
Russia, Leningrad region	Saint Petersburg, Leningrad region, Russia, 198205
Russia, Moscow region	Moscow, Moscow region, Russia, 125284
Russia, Moscow region	Moscow, Moscow region, Russia, 129110
Russia, Nizhny Novgorod region	Nizhny Novgorod, Nizhny Novgorod region, Russia
Russia, Novosibirsk region	Novosibirsk, Novosibirsk region, Russia, 630091
Russia, Sakha Republic	Yakutsk, Sakha Republic, Russia, 677008
Russia, Saratov region	Saratov, Saratov region, Russia, 410028

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company